Siemens Engineers a Two-Track Strategy: Chipmaking AI Deals and a Slow-Burn Healthineers Exit

Siemens is threading a needle between high-tech expansion and corporate simplification, laying out fresh details on both its deepening ties with Taiwan Semiconductor Manufacturing Co. (TSMC) and the long-awaited separation of its Healthineers medical technology unit. The moves underscore a conglomerate determined to plant its flag in the artificial intelligence era while methodically trimming its sprawling portfolio.

The Munich-based industrial group has secured official certification for its electronic design automation (EDA) software across TSMC’s most advanced chipmaking processes, including the cutting-edge N3A, N2P, and A16 nodes. At the heart of the expanded collaboration is the newly unveiled “Fuse EDA AI System,” an agent-based platform that automates large swaths of the semiconductor design workflow. Siemens’ tools will also support silicon photonics design and verification, while its Solido software has been integrated for aging simulation in TSMC’s A14 process.

The certifications place Siemens alongside established EDA heavyweights Cadence and Synopsys as a key partner in the TSMC ecosystem. For Siemens, the move opens a direct channel into the booming chip-design market, where demand is being supercharged by the global AI buildout. The company’s software portfolio is now embedded in the production of the world’s most sophisticated semiconductors, giving it a recurring revenue stream that is far removed from its traditional factory-automation roots.

Yet even as the software business races ahead, the industrial core is holding its own. Siemens reported first-quarter 2026 order intake growth of 10 percent on a comparable basis, with a book-to-bill ratio of 1.11 — meaning incoming orders are outpacing revenue. Sales rose 8 percent over the same period. The next major checkpoint arrives on May 13, 2026, when the company releases second-quarter results, with particular attention likely to fall on the Digital Industries segment.

Should investors sell immediately? Or is it worth buying Siemens?

Shareholders watching the stock have reason for cautious optimism. Siemens shares currently trade around €242.70, roughly 3 percent above their 200-day moving average. The stock has gained nearly 24 percent over the past twelve months. On a shorter timeframe, the picture is even brighter: the shares have climbed about 14 percent in the last month alone, leaving their 50-day average of €230.22 firmly in the rearview mirror. Analysts expect the dividend to rise to an estimated €5.64 per share for the current fiscal year, up from €5.35 last year.

But the headline strategic event remains the planned spin-off of Siemens Healthineers. Contrary to hopes for a swift separation, management has confirmed that the vote will take place at the ordinary annual general meeting in February 2027 — not at a special meeting this year. The transaction is being structured under Germany’s Umwandlungsgesetz (transformation law), with Siemens shareholders set to receive Healthineers shares directly into their portfolios.

The plan calls for transferring 30 percent of Siemens’ Healthineers stake to its own shareholders initially, with a medium-term target of reducing the holding to below 20 percent. Regulatory approval is still pending, and the deal cannot proceed until that clearance is secured.

The dual-track strategy — racing ahead in AI-enabled chip design while methodically unwinding a major healthcare investment — reflects a company that is both chasing tomorrow’s growth and tidying up yesterday’s structure. Whether the investments in industrial automation and EDA software are already translating into the bottom line will become clearer when Siemens reports its second-quarter numbers next month. For now, the market appears willing to give management the benefit of the doubt, rewarding the stock with double-digit monthly gains even as the Healthineers exit remains more than a year away.